Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Stock Price
SNYStock
$40.61−17.04%52W
Market Cap$97.31B
P/E11.08x
PEG Ratio27.79
Div yield4.12%
Beta0.58
SNY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-22.20%
Price vs S&P 500 (4W)-2.23%
PEG Ratio27.79
VGM Score57.16
P/E Ratio (Annual)11.08x
Indicated Dividend Yield (Annual)4.12%
SNY Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.28 | $1.35 | +5.59%(+$0.07) | |
| Q1 2026 | $1.15 | $1.24 | +7.26%(+$0.08) | |
| Q4 2025 | $0.95 | $1.02 | +7.38%(+$0.07) | |
| Q3 2025 | $1.76 | $1.90 | +8.14%(+$0.15) | |
| Q2 2025 | $1.12 | $1.02 | -9.05%(-$0.10) |
SNY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.76
3.76
3.77
3.77
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share) | B | D | B | 1.8x | 13.4% | 72.8% | -8.2% | $40.61 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Sanofi is a diversified pharmaceutical company focused on immunology, vaccines, and rare diseases. Its flagship product, Dupixent, accounts for approximately 30% of total revenue and is jointly commercialized with Regeneron. The company generates 45% of revenue from the United States, 20% from Europe, and 6% from China.